Performance of nuclear matrix protein 22 urine marker and voided urine cytology in the detection of urinary bladder tumors

Clinical Chemistry and Laboratory Medicine

Volumn 49, Issue 2, 2011, Pages 311-316

  Smrkolj, Tomaž ^a   Mihelič, Miro ^a   Sedlar, Aleš ^a   Sterle, Igor ^a   Osredkar, Joško ^a   Sedmak, Boris ^a  

^a UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

Author keywords

cystoscopy; nuclear matrix protein 22; urinary bladder neoplasm; voided urinary cytology

Indexed keywords

NUCLEAR MATRIX PROTEIN 22; TUMOR MARKER;

AGED; ARTICLE; BLADDER TUMOR; CANCER DIAGNOSIS; CONTROLLED CLINICAL TRIAL; CYSTOSCOPY; DIAGNOSTIC TEST ACCURACY STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; POINT OF CARE TESTING; PRIORITY JOURNAL; PROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; TRANSURETHRAL RESECTION; URINALYSIS; URINE CYTOLOGY;

AGED; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; NEOPLASM STAGING; NUCLEAR PROTEINS; POINT-OF-CARE SYSTEMS; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS;

EID: 79952098896     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/CCLM.2011.038     Document Type: Article

References (19)

1. Ferlay J, Parkin DM, Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 2010;46:765-81.
2. Lau P, Chin JL, Pautler S, Razvi H, Izawa JI. NMP22 is predictive of recurrence in high-risk superficial bladder cancer patients. Can Urol Assoc J 2009;3:454-8.
3. Jamshidian H, Kor K, Djalali M. Urine concentration of nuclear matrix protein 22 for diagnosis of transitional cell carcinoma of bladder. Urol J 2008;5:243-7.
4. Bubendorf L, Dalquen P, Savic S. Cytology of the urinary tract: between uncertainty and clarity. Pathologe 2009;30(Suppl 2): 173-8.
5. Kumar A, Kumar R, Gupta NP. Comparison of NMP22 BladderChek test and urine cytology for the detection of recurrent bladder cancer. Jpn J Clin Oncol 2006;36:172-5.
6. Sun Y, He DL, Ma Q, Wan XY, Zhu GD, Li L, et al. Comparison of seven screening methods in the diagnosis of bladder cancer. Chin Med J 2006;119:1763-71. (Pubitemid 44768604)
7. Mansoor I, Calam RR, Al-Khafaji B. Role of urinary NMP-22 combined with urine cytology in follow-up surveillance of recurring superficial bladder urothelial carcinoma. Anal Quant Cytol Histol 2008;30:25-32. (Pubitemid 351312097)
8. Gupta NP, Sharma N, Kumar R. Nuclear matrix protein 22 as adjunct to urine cytology and cystoscopy in follow-up of superficial TCC of urinary bladder. Urology 2009;73:592-6.
9. Sobin LH, Wittekind Ch, editors. In: TNM classification of malignant tumours, 6th ed. New York: Wiley-Liss, 2002:264.
10. Sauter G, Algaba F, Amin M, Busch C, Cheville J, Gasser T, et al. Tumours of the urinary system: non-invasive urothelial neoplasias. In: Eble JN, Sauter G, Epstein JI, Sesterhenn I, editors. WHO classification of tumours of the urinary system and male genital organs. Lyon: IARCC Press, 2004:29-34.
11. Herman MP, Svatek RS, Lotan Y, Karakiewizc PI, Shariat SF. Urine-based biomarkers for the early detection and surveillance of non-muscle invasive bladder cancer. Minerva Urol Nefrol 2008;60:217-35.
12. Babjuk M, Oosterlinck W, Sylvester R, Kaasinen E, Bohle A, Palou-Redorta J. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder. Eur Urol 2008;54:303-14.
13. Stenzl A, Cowan NC, De Santis M, Jakse G, Kuczyk MA, Merseburger AS, et al. The updated EAU guidelines on muscle-invasive and metastatic bladder cancer. Eur Urol 2009;55: 815-25.
14. Budman LI, Kassouf W, Steinberg JR. Biomarkers for detection and surveillance of bladder cancer. Can Urol Assoc J 2008;2: 212-21.
15. Alvarez A, Lokeshwar VB. Bladder cancer biomarkers: current developments and future implementation. Curr Opin Urol 2007;17:341-6. (Pubitemid 47344622)
16. Konety BR. Molecular markers in bladder cancer: a critical appraisal. Urol Oncol 2006;24:326-37. (Pubitemid 43963409)
17. Raina R, Pahlajani G, Ponsky LE, Agarwal A, Zippe CD. The clinical utility of atypical cytology is significantly increased in both screening and monitoring for bladder cancer when indexed with nuclear matrix protein-22. BJU Int 2008;102:297-300. (Pubitemid 352019207)
18. Kapila K, Kehinde EO, Anim JT, Mojiminiyi OA, Vinsu A, George SS, et al. Could nuclear matrix protein 22 (NMP22) play a role with urine cytology in screening for bladder cancer? - experience at Kuwait University. Cytopathology 2008;19: 369-74.
19. Shariat SF, Marberger MJ, Lotan Y, Sanchez-Carbayo M, Zippe C, Ludecke G, et al. Variability in the performance of nuclear matrix protein 22 for the detection of bladder cancer. J Urol 2006;176:919-26. (Pubitemid 44160707)